Publication Name	World Journal of Gastroenterology
Manuscript ID	106939
Country	China

Received	2025-03-11 02:14
Peer-Review Started	2025-03-11 02:14
To Make the First Decision
Return for Revision	2025-04-17 01:02
Revised	2025-04-23 19:26
Second Decision	2025-05-23 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-05-23 03:32
Articles in Press	2025-05-23 03:32
Publication Fee Transferred	2025-04-24 03:27
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-06-03 08:43
Publish the Manuscript Online	2025-06-06 03:09

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer
Manuscript Source	Unsolicited Manuscript
All Author List	Zhao Gao, Xiao-Yan Wang, Zhi-Gang Shen, Jia-Hua Liu, Xiao-Yun Wang, Shi-Kai Wu and Xuan Jin
ORCID	Author(s) ORCID Number Zhao Gao http://orcid.org/0009-0007-6128-4042 Shi-Kai Wu http://orcid.org/0009-0003-9525-4870 Xuan Jin http://orcid.org/0000-0002-9665-5356
Funding Agency and Grant Number	Funding Agency Grant Number National High Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital) No. 2022CR65
Corresponding Author	Shi-Kai Wu, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. skywu4923@sina.cn
Key Words	Microsatellite stable; RAS mutation; Metastatic colorectal cancer; Immune checkpoint inhibitors; Programmed death 1
Core Tip	This manuscript addresses to evaluate the effectiveness and safety of chemotherapy combined with bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line regimen for microsatellite stable metastatic colorectal cancer. As there is currently no clinical data on the second-line treatment of advanced colorectal cancer with the combination of immunotherapy, anti-angiogenic drugs, and anti-programmed death 1 immunotherapy, we conducted a multicenter retrospective cohort clinical study to explore the safety and efficacy of this triplet therapy in second-line treatment of advanced colorectal cancer patients.
Publish Date	2025-06-06 03:09
Citation	<p>Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer. <i>World J Gastroenterol</i> 2025; 31(21): 106939</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i21/106939.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i21.106939

Full Article (PDF)	WJG-31-106939-with-cover.pdf
STROBE Statement	106939-STROBE-statement.pdf
Manuscript File	106939_Auto_Edited_061015.docx
Answering Reviewers	106939-answering-reviewers.pdf
Audio Core Tip	106939-audio.m4a
Biostatistics Review Certificate	106939-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	106939-conflict-of-interest-statement.pdf
Copyright License Agreement	106939-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	106939-foundation-statement.PDF
Signed Informed Consent Form(s) or Document(s)	106939-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	106939-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	106939-non-native-speakers.pdf
Supplementary Material	106939-supplementary-material.pdf
Peer-review Report	106939-peer-reviews.pdf
Scientific Misconduct Check	106939-scientific-misconduct-check.png
Scientific Editor Work List	106939-scientific-editor-work-list.pdf
CrossCheck Report	106939-crosscheck-report.pdf